Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370). (Q52666574)
Jump to navigation
Jump to search
scientific article published on 5 March 2018
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370). |
scientific article published on 5 March 2018 |
Statements
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370). (English)
George Blumenschein
David R Spigel
Craig Reynolds
David Waterhouse
Edward B Garon
Jason Chandler
Sunil Babu
Paul Thurmes
Alexander Spira
Robert Jotte
Jin Zhu
Wen Hong Lin
5 March 2018
13
5
682-688